Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The delivery of effective therapeutic cancer vaccination.

× No keyword cloud information.

10 in total

1. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer.

Authors: A Troy; P Davidson; C Atkinson; D Hart
Journal: J Urol Date: 1998-07 Impact factor: 7.450

2. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Authors: Eric J Small; Paul F Schellhammer; Celestia S Higano; Charles H Redfern; John J Nemunaitis; Frank H Valone; Suleman S Verjee; Lori A Jones; Robert M Hershberg
Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544

3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors: Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal: N Engl J Med Date: 2010-07-29 Impact factor: 91.245

4. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.

Authors: Davide Brusa; Sara Carletto; Giuseppina Cucchiarale; Paolo Gontero; Alessandro Greco; Mariagrazia Simone; Ugo Ferrando; Alessandro Tizzani; Lina Matera
Journal: Prostate Date: 2010-09-01 Impact factor: 4.104

Review 5. Prostate cancer as a model for tumour immunotherapy.

Authors: Charles G Drake
Journal: Nat Rev Immunol Date: 2010-08 Impact factor: 53.106

6. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.

Authors: Viggo F Van Tendeloo; Ann Van de Velde; Ann Van Driessche; Nathalie Cools; Sébastien Anguille; Kristin Ladell; Emma Gostick; Katrien Vermeulen; Katrien Pieters; Griet Nijs; Barbara Stein; Evelien L Smits; Wilfried A Schroyens; Alain P Gadisseur; Inge Vrelust; Philippe G Jorens; Herman Goossens; I Jolanda de Vries; David A Price; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama; Zwi N Berneman
Journal: Proc Natl Acad Sci U S A Date: 2010-07-14 Impact factor: 11.205

7. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors: Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal: Blood Date: 2009-10-30 Impact factor: 22.113

Review 8. Dendritic cells in cancer immunotherapy.

Authors: Annelie Vulink; Kristen J Radford; Cornelis Melief; Derek N J Hart
Journal: Adv Cancer Res Date: 2008 Impact factor: 6.242

9. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors: Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544

10. Identification of a cell of origin for human prostate cancer.

Authors: Andrew S Goldstein; Jiaoti Huang; Changyong Guo; Isla P Garraway; Owen N Witte
Journal: Science Date: 2010-07-30 Impact factor: 47.728

10 in total

1 in total

Review 1. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.

Authors: Sarah I M Sutherland; Xinsheng Ju; L G Horvath; Georgina J Clark
Journal: Front Immunol Date: 2021-03-29 Impact factor: 7.561

1 in total